11 Liver Disease Clinical Trials in Indianapolis, IN (2026)

Q: How do I join a clinical trial in Indianapolis?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Indianapolis research site will contact you.

Recruiting Liver Disease Studies in Indianapolis

NCT03228290Recruiting

Functional Assessment in Liver Transplantation

This will be a prospective cohort study of patients with liver disease. Subjects will undergo geriatric assessments of frailty, functional status, and disability using functional status measures at ba...

Indianapolis, IN5,000 participantsUniversity of California, San Francisco

View Study Details

NCT00345930Recruiting

DILIN - Prospective Study

The purpose of this study is to identify individuals who have suffered a liver injury arising as an idiosyncratic reaction to a prescription drug or a complementary and alternative medicine. Recently ...

Indianapolis, IN4,000 participantsDuke University

View Study Details

NCT05733832Recruiting

A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease

Patients with complications of advanced liver disease often have difficulties after hospital discharge that result in early hospital readmission. Poor outcomes for these patients during this transitio...

Indianapolis, INNA1,000 participantsIndiana University

View Study Details

NCT07191886Recruiting

Measuring Patient Reported Needs in Outpatient Liver Disease Management

This prospective study aims to assess health-related social needs (HRSNs) among patients with chronic liver disease (CLD) receiving outpatient care at Indiana University Health. Patients with CLD ofte...

Indianapolis, IN400 participantsIndiana University

View Study Details

NCT06613698Recruiting

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease....

Indianapolis, INPHASE2393 participantsGlaxoSmithKline

View Study Details

NCT04250259Recruiting

SAMe Trial for Patients With Alcoholic Cirrhosis

The proposed of this randomized, double blinded, placebo-controlled study is to assess the effect of SAMe compared to placebo in patients with alcoholic cirrhosis Child Class A and B. The primary obje...

Indianapolis, INPHASE2196 participantsIndiana University

View Study Details

NCT04862221Recruiting

TReatment for ImmUne Mediated PathopHysiology

TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will de...

Indianapolis, INPHASE2163 participantsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

View Study Details

NCT06374875Recruiting

Fibrosis Lessens After Metabolic Surgery

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity...

Indianapolis, INPHASE4120 participantsAli Aminian

View Study Details

NCT07143968Recruiting

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

The purpose of this research study is to test the safety and effectiveness of the study drug, resmetirom, in participants with MASLD and HIV. This is a research study to test a drug that is already on...

Indianapolis, INPHASE2120 participantsNaga P. Chalasani

View Study Details

NCT06396897Recruiting

Hospital @ Home Model of Care for Cirrhosis

The purpose of this study is to work with patients diagnosed with end-stage liver disease to understand their perspectives on the Health at Home (H@H) Program, including desired outcomes and expectati...

Indianapolis, INNA30 participantsIndiana University

View Study Details

NCT06825559Recruiting

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

Evaluating Pharmacokinetic and safety of Saroglitazar Magnesium 1 mg when dosed on alternate days in subjects having moderate hepatic impairment with cirrhosis due to cholestatic liver disease...

Indianapolis, INPHASE16 participantsZydus Therapeutics Inc.

View Study Details

About Liver Disease Clinical Trials in Indianapolis

Chronic liver disease encompasses conditions that damage the liver over time, including cirrhosis, hepatitis, and fatty liver disease. The liver plays a crucial role in digestion, metabolism, and detoxification. Treatment depends on the cause and may include medications, lifestyle changes, or liver transplant.

There are currently 11 liver disease clinical trials recruiting participants in Indianapolis, IN. These studies are seeking a combined 11,428 participants. Research is being sponsored by University of California, San Francisco, Duke University, Indiana University and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Liver Disease Clinical Trials in Indianapolis — FAQ

Are there liver disease clinical trials in Indianapolis?

Yes, there are 11 liver disease clinical trials currently recruiting in Indianapolis, IN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Indianapolis?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Indianapolis research site will contact you about next steps.

Are clinical trials in Indianapolis free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Indianapolis studies also compensate for your time and travel.

What liver disease treatments are being tested?

The 11 active trials in Indianapolis are testing new therapies including novel drugs, biologics, and treatment approaches for liver disease.

Data updated July 21, 2026 from ClinicalTrials.gov